tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Erasca’s Strategic Advancements in RAS Programs Justify Buy Rating
PremiumRatingsErasca’s Strategic Advancements in RAS Programs Justify Buy Rating
2M ago
Erasca Reports Progress and Financial Stability in Q2 2025
Premium
Company Announcements
Erasca Reports Progress and Financial Stability in Q2 2025
2M ago
Erasca files $500M mixed securities shelf
Premium
The Fly
Erasca files $500M mixed securities shelf
2M ago
Erasca’s Strategic Advancements and Promising RAS-Targeting Therapies Justify Buy Rating
PremiumRatingsErasca’s Strategic Advancements and Promising RAS-Targeting Therapies Justify Buy Rating
5M ago
Erasca reports Q1 EPS (11c), consensus (13c)
Premium
The Fly
Erasca reports Q1 EPS (11c), consensus (13c)
5M ago
Erasca announces IND clearance, prioritizing of RAS-targeting franchise
Premium
The Fly
Erasca announces IND clearance, prioritizing of RAS-targeting franchise
5M ago
Promising Clinical Developments and Strategic Acquisitions Drive Buy Rating for Naporafenib and Molecular Glue Assets
PremiumRatingsPromising Clinical Developments and Strategic Acquisitions Drive Buy Rating for Naporafenib and Molecular Glue Assets
6M ago
Erasca, Inc. Reports 2024 Financial and Strategic Progress
Premium
Company Announcements
Erasca, Inc. Reports 2024 Financial and Strategic Progress
6M ago
Erasca reports Q4 EPS (11c), consensus (13c)
Premium
The Fly
Erasca reports Q4 EPS (11c), consensus (13c)
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100